Rheumatoid arthritis (RA) is a chronic inflammatory disease causing joint damage and disability. Early diagnosis and treatment are crucial for optimal outcomes, with well-characterized risk factors such as high disease activity, autoantibodies, and early damage. Treatment involves measuring disease activity, using treatment-to-target strategies, and employing conventional and novel biologic and non-biologic disease-modifying antirheumatic drugs (DMARDs). Once stringent remission or low disease activity is achieved, dose reduction or interval increases should be considered. While many patients respond well to current therapies, new treatments are needed. This seminar reviews current insights into RA's genetics, etiology, pathophysiology, epidemiology, assessment, therapies, and unmet needs. RA is a prevalent chronic inflammatory disease affecting joints and other organs. Recent advances in treatment have significantly reduced long-term damage and functional decline. This seminar highlights recent insights into RA's epidemiology, diagnosis, etiology, pathophysiology, treatment targets, and strategies. Despite progress, pathogenetic insights remain limited, and novel therapies often fail. There is a significant unmet need for deep remission in RA. RA has a significant burden on individuals and society, with risk factors including smoking and socioeconomic status. Genetic studies have identified over 100 loci associated with RA risk, with HLA-DRB1 playing a major role. Epigenetic factors also contribute to RA pathogenesis. The pathophysiology of RA involves autoimmune responses to citrullinated self-proteins, leading to joint damage and systemic complications. The role of the microbiome in RA is also being explored. Diagnosis of RA lacks specific criteria, with clinical features such as joint swelling and elevated inflammatory markers. New classification criteria have improved early disease detection. Disease activity is assessed using composite measures, with treatment targets including remission or low disease activity. Treatment strategies involve DMARDs, biologics, and other therapies, with a focus on achieving and maintaining treatment targets. DMARDs, including synthetic and biological agents, are used to modify disease progression. Glucocorticoids are used in combination with DMARDs but carry significant side effects. Biologic agents target specific pathways, such as TNF, IL-6, and IL-17, with varying efficacy. Tofacitinib and baricitinib are novel JAK inhibitors showing promise. Adverse events, including infections and reactivation of tuberculosis, are common with biologics. Many targeted therapies have failed to show clinical benefit, highlighting the complexity of RA pathogenesis. Open questions remain regarding the efficacy of different therapies and the need for precision medicine approaches. Future therapies aim to improve predictability and outcomes, with a focus on causative treatments. Overall, early diagnosis and treatment are critical for preventing joint damage and improving quality of life in RA patients.Rheumatoid arthritis (RA) is a chronic inflammatory disease causing joint damage and disability. Early diagnosis and treatment are crucial for optimal outcomes, with well-characterized risk factors such as high disease activity, autoantibodies, and early damage. Treatment involves measuring disease activity, using treatment-to-target strategies, and employing conventional and novel biologic and non-biologic disease-modifying antirheumatic drugs (DMARDs). Once stringent remission or low disease activity is achieved, dose reduction or interval increases should be considered. While many patients respond well to current therapies, new treatments are needed. This seminar reviews current insights into RA's genetics, etiology, pathophysiology, epidemiology, assessment, therapies, and unmet needs. RA is a prevalent chronic inflammatory disease affecting joints and other organs. Recent advances in treatment have significantly reduced long-term damage and functional decline. This seminar highlights recent insights into RA's epidemiology, diagnosis, etiology, pathophysiology, treatment targets, and strategies. Despite progress, pathogenetic insights remain limited, and novel therapies often fail. There is a significant unmet need for deep remission in RA. RA has a significant burden on individuals and society, with risk factors including smoking and socioeconomic status. Genetic studies have identified over 100 loci associated with RA risk, with HLA-DRB1 playing a major role. Epigenetic factors also contribute to RA pathogenesis. The pathophysiology of RA involves autoimmune responses to citrullinated self-proteins, leading to joint damage and systemic complications. The role of the microbiome in RA is also being explored. Diagnosis of RA lacks specific criteria, with clinical features such as joint swelling and elevated inflammatory markers. New classification criteria have improved early disease detection. Disease activity is assessed using composite measures, with treatment targets including remission or low disease activity. Treatment strategies involve DMARDs, biologics, and other therapies, with a focus on achieving and maintaining treatment targets. DMARDs, including synthetic and biological agents, are used to modify disease progression. Glucocorticoids are used in combination with DMARDs but carry significant side effects. Biologic agents target specific pathways, such as TNF, IL-6, and IL-17, with varying efficacy. Tofacitinib and baricitinib are novel JAK inhibitors showing promise. Adverse events, including infections and reactivation of tuberculosis, are common with biologics. Many targeted therapies have failed to show clinical benefit, highlighting the complexity of RA pathogenesis. Open questions remain regarding the efficacy of different therapies and the need for precision medicine approaches. Future therapies aim to improve predictability and outcomes, with a focus on causative treatments. Overall, early diagnosis and treatment are critical for preventing joint damage and improving quality of life in RA patients.